Journal
CELL CYCLE
Volume 15, Issue 17, Pages 2256-2262Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/15384101.2016.1208872
Keywords
breast; EZH2; prostate; Polycomb; prognosis; PRC2; solid tumors; tumor suppressor
Categories
Funding
- European Research Council (ERC-Stg, REPODDID)
- Association pour la Recherche contre le Cancer (ARC)
Ask authors/readers for more resources
EZH2, the main catalytic component of the Polycomb Repressive Complex 2 (PRC2) is apparently upregulated in most solid tumors. Furthermore its expression generally associates with poor prognosis. It was proposed that this correlation reflects a causal event, EZH2 mediating the silencing of key tumor suppressor loci. In contrast, we recently showed that EZH2 is dispensable for solid tumor development and that its elevated expression reflects the abnormally high proliferation rate of cancer cells. Here, we investigate the functional association between EZH2 expression and silencing of key tumor suppressor loci and further illustrate the confounding effect of proliferation on EZH2s association to outcome.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available